ArticleWorld journal of gastroenterology2025
Unveiling Yiyi Fuzi Baijiang powder: Microecological and network pharmacology approach to ulcerative colitis treatment.
Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Yiyi Fuzi Baijiang formula protects against DSS-induced colitis by orchestrating the gut barrier-microbiota-metabolism axis.Chinese medicine · 2026Article
- Herbal medicine beyond probiotics: Yiyi Fuzi Baijiang powder and the holistic regulation of gut microbiota in ulcerative colitis.World journal of gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundYiyi Fuzi Baijiang powder (YFB), a classic Chinese medicine, significantly affects ulcerative colitis (UC). However, it remains unclear whether YFB plays a therapeutic role by improving the intestinal flora of UC patients and its active ingredients.
aimTo explore the mechanisms of action of YFB in treating UC.
methodsA mouse model of UC was established by drinking 2.5% dextran sulfate sodium (DSS). Mice were treated with YFB. 16S rDNA sequencing was used to detect changes in intestinal flora and perform functional predictions. Corresponding target genes of core active ingredients in YFB and UC were obtained using multiple database retrievals and then used to predict the mechanism of overlapping targets. After screening core ingredients and target genes, AutoDock software was used for molecular docking, and the best binding target was selected to verify binding activity.
resultsYFB improved DSS-UC mice by restoring body weight, reducing disease activity index, increasing water and food intake, and alleviating diarrhea and local histopathological damage. YFB enhanced beta diversity, decreased pathogenic bacteria such as
conclusionYFB treats UC by reducing harmful bacteria and boosting probiotics to restore intestinal balance, while potentially influencing signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.